Trials / Completed
CompletedNCT00160238
Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy
A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Betahistine 24 mg bid (Betaserc) |
Timeline
- Start date
- 2003-01-01
- First posted
- 2005-09-12
- Last updated
- 2006-12-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00160238. Inclusion in this directory is not an endorsement.